Abstract:Abstract Background Progressive multiple sclerosis (PMS) is an uncommon and severe subtype of MS that worsens gradually and leads to irreversible disabilities in young adults. Currently, there are no applicable or reliable biomarkers to distinguish PMS from relapsing–remitting multiple sclerosis (RRMS). Previous studies have demonstrated that dysfunction of N 6-methyladenosine (m6A) RNA modification is relevant to many neurological disorders. Thus, the aim of this study was to explore the diagnostic biomarkers for PMS based on m6A regulatory genes in the cerebrospinal fluid (CSF). Methods Gene expression matrices were downloaded from the ArrayExpress database. Then, we identified differentially expressed m6A regulatory genes between MS and non-MS patients. MS clusters were identified by consensus clustering analysis. Next, we analyzed the correlation between clusters and clinical characteristics. The random forest (RF) algorithm was applied to select key m6A-related genes. The support vector machine (SVM) was then used to construct a diagnostic gene signature. Receiver operating characteristic (ROC) curves were plotted to evaluate the accuracy of the diagnostic model. In addition, CSF samples from MS and non-MS patients were collected and used for external validation, as evaluated by an m6A RNA Methylation Quantification Kit and by real-time quantitative polymerase chain reaction. Results The 13 central m6A RNA methylation regulators were all upregulated in MS patients when compared with non-MS patients. Consensus clustering analysis identified two clusters, both of which were significantly associated with MS subtypes. Next, we divided 61 MS patients into a training set (n = 41) and a test set (n = 20). The RF algorithm identified eight feature genes, and the SVM method was successfully applied to construct a diagnostic model. ROC curves revealed good performance. Finally, the analysis of 11 CSF samples demonstrated that RRMS samples exhibited significantly higher levels of m6A RNA methylation and higher gene expression levels of m6A-related genes than PMS samples. Conclusions The dynamic modification of m6A RNA methylation is involved in the progression of MS and could potentially represent a novel CSF biomarker for diagnosing MS and distinguishing PMS from RRMS in the early stages of the disease.

MicroRNAs in blood and cerebrospinal fluid as diagnostic biomarkers of multiple sclerosis and to monitor disease progression

The role of microRNAs involved in the disorder of blood–brain barrier in the pathogenesis of multiple sclerosis

MicroRNAs in Cerebrospinal Fluid as Potential Biomarkers for Parkinson’s Disease and Multiple System Atrophy

A Meta-Analytic Review of the Value of Mirna for Multiple Sclerosis Diagnosis

A microRNA diagnostic biomarker for amyotrophic lateral sclerosis

MicroRNA in Multiple Sclerosis

Exosome‐associated miRNA profile as a prognostic tool for therapy response monitoring in multiple sclerosis patients

Association of MicroRNA Expression and Serum Neurofilament Light Chain Levels with Clinical and Radiological Findings in Multiple Sclerosis

Machine learning-driven diagnosis of multiple sclerosis from whole blood transcriptomics

miRNAs as Circulating Biomarkers for Alzheimer's Disease and Parkinson's Disease.

microRNA Expression and Its Association With Disability and Brain Atrophy in Multiple Sclerosis Patients Treated With Glatiramer Acetate

Identifying the Biomarkers of Multiple Sclerosis Based on Non-Coding RNA Signature.

Current and Future Biomarkers in Multiple Sclerosis

N6-Methyladenosine RNA modification in cerebrospinal fluid as a novel potential diagnostic biomarker for progressive multiple sclerosis

Circulating MicroRNAs As Diagnostic Biomarkers for Motor Neuron Disease.

Circulating microRNAs: Biomarkers of disease

The Diagnostic Value of Circulating Brain-Specific Micrornas for Ischemic Stroke

Circulating MicroRNA As Potential Source for Neurodegenerative Diseases Biomarkers

miRNA expression profiles in cerebrospinal fluid and blood of patients with Alzheimer’s disease and other types of dementia – an exploratory study

MicroRNAs associated with the pathogenesis of multiple sclerosis

Fluid biomarkers in multiple sclerosis: from current to future applications